FIELD: medicine, ophthalmology. SUBSTANCE: invention describes composition used for treatment of glaucoma and intraocular hypertensions and the use of EP1 agonists of prostanoid receptors that reduce intraocular pressure effectively but do not or reduce the pigmentation effect or iris. Prostaglandin analog as a EP1 selective agonist is applied on eye topically. Invention provides attenuation of adverse effect expressing as melanogenesis. EFFECT: enhanced and valuable properties of prostaglandins. 4 cl, 5 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF SYNTHESIS OF 13,14-DIHYDRO-17-PHENYL ANALOG OF PGF OR PGF | 1991 |
|
RU2073668C1 |
| METHOD OF SYNTHESIS OF 13,14-DIHYDRO-15(R)-17-PHENYL-18,19,20-TRINOR-PGF2α ESTER | 1993 |
|
RU2099325C1 |
| 1-ETHANOLAMIDE PGF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | 2001 |
|
RU2252212C2 |
| SUBSTITUTED CYCLOPENTANES, POSSESSING PROSTAGLANDIN ACTIVITY | 2009 |
|
RU2505530C2 |
| ALKYL-SUBSTITUTED CYCLIC AMINES AS SELECTIVE LIGANDS OF D3-DOPAMINE | 1997 |
|
RU2185372C2 |
| PROCESS FOR PREPARING DERIVATIVES OF 16-AMINO-18,19,20-TRINOR-PROSTAGLANDINE OR THEIR ACID ADDITION SALTS | 0 |
|
SU1093244A3 |
| DERIVATIVES OF 5-(2-IMIDAZOLINYLAMINO)-BENZ-IMIDAZOLE, PHARMACEUTICAL COMPOSITION | 1998 |
|
RU2193562C2 |
| PROSTAGLANDIN FALPHA DERIVATIVES FOR REDUCING INTRAOCULAR PRESSURE | 2018 |
|
RU2718744C2 |
| METHOD OF OBTAINING OPTICALLY ACTIVE COMPOUNDS OF PROSTAGLANDINE SERIES OR THEIR RACEMATES | 0 |
|
SU662008A3 |
| DERIVATIVES OF IMIDAZO[1,2-A]PYRIDINE, METHODS OF THEIR SYNTHESIS, PHARMACEUTICAL PREPARATION BASED ON THEREOF, METHOD OF INHIBITION OF GASTRIC ACID SECRETION, METHOD OF TREATMENT OF GASTROENTERIC INFLAMMATORY DISEASES AND METHOD OF TREATMENT OF STATES WITH HELICOBACTER PYLORI INFECTION | 1998 |
|
RU2193036C2 |
